Leerink Partners analyst Marc Goodman has maintained their bullish stance on DNLI stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Marc Goodman has given his Buy rating due to a combination of factors related to Denali Therapeutics’ promising developments and financial stability. The acceptance of the BLA for tividenofusp alfa for priority review, with a PDUFA date set for January 5, 2026, is a significant milestone. This application is supported by positive data from the Phase 1/2 study and ongoing Phase 2/3 COMPASS study, which bodes well for future regulatory submissions.
Furthermore, Denali’s alignment with the FDA regarding CSF heparin sulfate as a surrogate endpoint for DNL126 in Sanfilippo syndrome type A is encouraging. The company’s pipeline remains robust with ongoing studies and expected advancements in several programs. Financially, Denali is in a strong position with approximately $977 million in cash, projected to sustain operations into 2028. The commercial team is well-prepared for the potential launch of tividenofusp alfa, enhancing the company’s readiness for future growth.
In another report released yesterday, Bank of America Securities also reiterated a Buy rating on the stock with a $27.00 price target.
DNLI’s price has also changed moderately for the past six months – from $21.310 to $14.810, which is a -30.50% drop .